Literature DB >> 29676470

Role of miRNAs in lung cancer.

Arif Uddin1, Supriyo Chakraborty2.   

Abstract

Lung cancer (LC) is the leading cause of cancer-related deaths all over the world, among both men and women, with an incidence of over 200,000 new cases per year coupled with a very high mortality rate. LC comprises of two major clinicopathological categories: small-cell (SCLC) and nonsmall-cell lung carcinoma (NSCLC). The microRNAs (miRNAs) are small noncoding RNAs, usually 18-25 nucleotides long, which repress protein translation through binding to complementary target mRNAs. The miRNAs regulate many biological processes including cell cycle regulation, cellular growth, proliferation, differentiation, apoptosis, metabolism, neuronal patterning, and aging. This review summarizes the role of miRNAs expression in LC. It also provides information about the miRNAs as biomarker and therapeutic target for lung cancer. Understanding the role of miRNAs in LC may provide insights into the diagnosis and treatment strategy for LC.
© 2018 Wiley Periodicals, Inc.

Entities:  

Keywords:  lung cancer; miRNAs; small-cell and nonsmall-cell lung carcinoma

Year:  2018        PMID: 29676470     DOI: 10.1002/jcp.26607

Source DB:  PubMed          Journal:  J Cell Physiol        ISSN: 0021-9541            Impact factor:   6.384


  17 in total

1.  miR-17-5p-CXCL14 axis related transcriptome profile and clinical outcome in diffuse gliomas.

Authors:  Ailiang Zeng; Jianxin Yin; Zheng Wang; Chuanbao Zhang; Rui Li; Zhuoran Zhang; Wei Yan; Yongping You
Journal:  Oncoimmunology       Date:  2018-09-11       Impact factor: 8.110

2.  Tumor Suppressor 4.1N/EPB41L1 is Epigenetic Silenced by Promoter Methylation and MiR-454-3p in NSCLC.

Authors:  Qin Yang; Lin Zhu; Mao Ye; Bin Zhang; Peihe Zhan; Hui Li; Wen Zou; Jing Liu
Journal:  Front Genet       Date:  2022-06-20       Impact factor: 4.772

3.  Identification of Potential Prostate Cancer-Related Pseudogenes Based on Competitive Endogenous RNA Network Hypothesis.

Authors:  Tao Jiang; Junjie Guo; Zhongchun Hu; Ming Zhao; Zhenggang Gu; Shu Miao
Journal:  Med Sci Monit       Date:  2018-06-20

4.  A novel semi-supervised model for miRNA-disease association prediction based on [Formula: see text]-norm graph.

Authors:  Cheng Liang; Shengpeng Yu; Ka-Chun Wong; Jiawei Luo
Journal:  J Transl Med       Date:  2018-12-14       Impact factor: 5.531

5.  microRNA-605 inhibits the oncogenicity of non-small-cell lung cancer by directly targeting Forkhead Box P1.

Authors:  Wei Zhou; Ruichao Li
Journal:  Onco Targets Ther       Date:  2019-05-17       Impact factor: 4.147

6.  MiR-1246 Promotes Metastasis and Invasion of A549 cells by Targeting GSK-3β‒Mediated Wnt/β-Catenin Pathway.

Authors:  Fan Yang; Hairong Xiong; Li Duan; Qian Li; Xin Li; Yongqin Zhou
Journal:  Cancer Res Treat       Date:  2019-03-04       Impact factor: 4.679

7.  Effects and mechanism of microRNA‑218 against lung cancer.

Authors:  Yan Chen; Ji-Lin Yang; Zhen-Zhen Xue; Qiu-Chen Cai; Chun Hou; Hong-Juan Li; Liu-Xin Zhao; Yin Zhang; Cheng-Wei Gao; Li Cong; Tian-Zuo Wang; Dong-Mei Chen; Guo-Sheng Li; Shi-Qing Luo; Qian Yao; Chan-Juan Yang; Qi-Shun Zhu; Chuan-Hai Cao
Journal:  Mol Med Rep       Date:  2020-11-12       Impact factor: 2.952

8.  MiR-596 activated by EP300 controls the tumorigenesis in epithelial ovarian cancer by declining BRD4 and KPNA4.

Authors:  Deying Wang; Yulan Cui; Aili Xu; Lin Zhao; Peiling Li
Journal:  Cancer Cell Int       Date:  2020-09-11       Impact factor: 5.722

Review 9.  Lamins in Lung Cancer: Biomarkers and Key Factors for Disease Progression through miR-9 Regulation?

Authors:  Julien Guinde; Diane Frankel; Sophie Perrin; Valérie Delecourt; Nicolas Lévy; Fabrice Barlesi; Philippe Astoul; Patrice Roll; Elise Kaspi
Journal:  Cells       Date:  2018-07-16       Impact factor: 6.600

Review 10.  Current Landscape of Epigenetics in Lung Cancer: Focus on the Mechanism and Application.

Authors:  Yuan-Xiang Shi; De-Qiao Sheng; Lin Cheng; Xin-Yu Song
Journal:  J Oncol       Date:  2019-12-12       Impact factor: 4.375

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.